ArticleResearch square2026
Development and validation of an interpretable machine learning model for predicting the risk of 8-year all-cause mortality in Cardiovascular-Kidney-Metabolic Syndrome among older adults: A multicenter and cohort study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background: Cardiovascular-kidney-metabolic syndrome (CKM) among elder adults due to age-related physiology is a high burden, but long-term mortality risk prediction is understudied. This study aims to develop and validate an explainable machine learning model to predict 8-year all-cause mortality. Methods: This study used HRS (2012-2020) and CHARLS (2011-2020) database, performed data cleaning and multiple imputation, plotted Kaplan-Meier curves with log-rank tests, conducted competing risk analyses, and pooled estimates using Rubin's rules. Cox regression was used to adjust for confounders. In CHARLS, variables were selected using LASSO (retained if selected ≥ 70%), after sensitivity and collinearity checks. We compared six survival models with 10-fold cross-validation and evaluated performance with AUC, DCA, calibration curves, and the Brier score, with external validation in HRS. SHAP was used to explain feature importance. Results: 8,473 participants (CHARLS 4,460; HRS 4,013) was included. Pooled 8-year mortality by CKM stages 0-4 was: HRS 9.2%, 4.94%, 9.14%, 12.57% and 18.97%; CHARLS 15.69%, 9.92%, 16.76%, 25.51% and 26.19%. Each one-stage increase in CKM was associated with a 40% and 15% higher mortality risk (both P < 0.001). The Cox model performed best: internal AUC 76.7% (95%CI: 76.5%-76.8%); external AUC 76.6% (95%CI: 76.2-77.0). Top three SHAP features: age, smoking and cystatin C. Conclusions: The Cox model showed good discrimination, calibration, and interpretability for predicting 8-year mortality risk in older adults with CKM syndrome across Chinese and American populations. Research findings indicate that interventions targeting the predictors cystatin C and gait speed may help reduce the long-term risk of mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.